Advertisement

The effects of antidepressant drugs and 5-HT1A agonists on human sleep

  • Spilios V. Argyropoulos
  • Sue J. Wilson
  • David J. Nutt

Abstract

Antidepressants, in general, affect sleep. The most consistent effect is suppression of the rapid eye movement (REM) sleep, and this is observed both in healthy volunteers and depressed patients. REM is affected most by drugs that block the reuptake of serotonin, like the selective serotonin-reuptake inhibitors (SSRIs) and the serotonin-noradrenaline-reuptake inhibitors (SNRIs). Further, these drugs often disrupt sleep continuity. The 5-HT1A agonist anxiolytics (azapirones) like buspirone show an REM suppressant effect but they do not affect sleep continuity. We discuss this difference in terms of likely explanatory 5-HT mechanisms for the above effects. With chronic treatment, there is gradual diminution of the sleep effects of the SSRIs. Finally, we discuss the subjective sleep effects of these drugs, which are often different from the polysomnographic ones.

Keywords

Slow Wave Sleep Biol Psychiatry Subjective Sleep Tryptophan Depletion Sleep Continuity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Reference

  1. 1.
    Anderson IM, Nutt DJ, Deakin JF (2000) Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. J Psychopharmacol 14: 3–20PubMedGoogle Scholar
  2. 2.
    Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU (2005) Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 19: 567–596PubMedCrossRefGoogle Scholar
  3. 3.
    Delgado PL, Miller HL, Salomon RM, Licinio J, Krystal JH, Moreno FA, Heninger GR, Charney DS (1999) Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol Psychiatry 46: 212–220PubMedCrossRefGoogle Scholar
  4. 4.
    Bell C, Forshall S, Adrover M, Nash J, Hood S, Argyropoulos S, Rich A, Nutt DJ (2002) Does 5-HT restrain panic? A tryptophan depletion study in panic disorder patients recovered on paroxetine. J Psychopharmacol 16: 5–14PubMedGoogle Scholar
  5. 5.
    Argyropoulos SV, Hood SD, Adrover M, Bell CJ, Rich AS, Nash JR, Rich NC, Witchel HJ, Nutt DJ (2004) Tryptophan depletion reverses the therapeutic effect of selective serotonin reuptake inhibitors in social anxiety disorder. Biol Psychiatry 56: 503–509PubMedCrossRefGoogle Scholar
  6. 6.
    Argyropoulos SV, Sandford JJ, Nutt DJ (2000) The psychobiology of anxiolytic drug. Part 2: Pharmacological treatments of anxiety. Pharmacol Ther 88: 213–227PubMedCrossRefGoogle Scholar
  7. 7.
    Thase ME (1999) Antidepressant treatment of the depressed patient with insomnia. J Clin Psychiatry 60Suppl 17: 28–31PubMedGoogle Scholar
  8. 8.
    Agargun MY, Kara H, Solmaz M (1997) Subjective sleep quality and suicidality in patients with major depression. J Psychiatr Res 31: 377–381PubMedCrossRefGoogle Scholar
  9. 9.
    Papadimitriou GN, Linkowski P (2005) Sleep disturbance in anxiety disorders. Int Rev Psychiatry 17: 229–236PubMedCrossRefGoogle Scholar
  10. 10.
    Rechtschaffen A, Kales A (1968) A manual of standardized terminology, techniques, and scoring system for sleep stages of human subjects. UCLA Brain Information Service/Brain Research Institute, Los AngelesGoogle Scholar
  11. 11.
    Argyropoulos SV, Hicks JA, Nash JR, Bell CJ, Rich AS, Nutt DJ, Wilson SJ (2003) Correlation of subjective and objective sleep measurements at different stages of the treatment of depression. Psychiatry Res 120: 179–190PubMedCrossRefGoogle Scholar
  12. 12.
    Kupfer DJ (1995) Sleep research in depressive illness: clinical implications — a tasting menu. Biol Psychiatry 38: 391–403PubMedCrossRefGoogle Scholar
  13. 13.
    Thase ME, Buysse DJ, Frank E, Cherry CR, Cornes CL, Mallinger AG, Kupfer DJ (1997) Which depressed patients will respond to interpersonal psychotherapy? The role of abnormal EEG sleep profiles. Am J Psychiatry 154: 502–509PubMedGoogle Scholar
  14. 14.
    Wilson S, Argyropoulos S (2005) Antidepressants and sleep: a qualitative review of the literature. Drugs 65: 927–947PubMedCrossRefGoogle Scholar
  15. 15.
    Monaca C, Boutrel B, Hen R, Hamon M, Adrien J (2003) 5-HT 1A/1B receptor-mediated effects of the selective serotonin reuptake inhibitor, citalopram, on sleep: studies in 5-HT 1A and 5-HT 1B knockout mice. Neuropsychopharmacology 28: 850–856PubMedGoogle Scholar
  16. 16.
    Gillin JC, Jernajczyk W, Valladares-Neto DC, Golshan S, Lardon M, Stahl SM (1994) Inhibition of REM sleep by ipsapirone, a 5HT1A agonist, in normal volunteers. Psychopharmacology (Berl) 116: 433–436CrossRefGoogle Scholar
  17. 17.
    Moore P, Gillin C, Bhatti T, DeModena A, Seifritz E, Clark C, Stahl S, Rapaport M, Kelsoe J (1998) Rapid tryptophan depletion, sleep electroencephalogram, and mood in men with remitted depression on serotonin reuptake inhibitors. Arch Gen Psychiatry 55: 534–539PubMedCrossRefGoogle Scholar
  18. 18.
    Bhatti T, Gillin JC, Seifritz E, Moore P, Clark C, Golshan S, Stahl S, Rapaport M, Kelsoe J (1998) Effects of a tryptophan-free amino acid drink challenge on normal human sleep electroencephalogram and mood. Biol Psychiatry 43: 52–59PubMedCrossRefGoogle Scholar
  19. 19.
    Voderholzer U, Hornyak M, Thiel B, Huwig-Poppe C, Kiemen A, Konig A, Backhaus J, Riemann D, Berger M, Hohagen F (1998) Impact of experimentally induced serotonin deficiency by tryptophan depletion on sleep EEG in healthy subjects. Neuropsychopharmacology 18: 112–124PubMedCrossRefGoogle Scholar
  20. 20.
    Arnulf I, Quintin P, Alvarez JC, Vigil L, Touitou Y, Lebre AS, Bellenger A, Varoquaux O, Derenne JP, Allilaire JF, Benkelfat C, Leboyer M (2002) Mid-morning tryptophan depletion delays REM sleep onset in healthy subjects. Neuropsychopharmacology 27: 843–851PubMedCrossRefGoogle Scholar
  21. 21.
    Feige B, Voderholzer U, Riemann D, Dittmann R, Hohagen F, Berger M (2002) Fluoxetine and sleep EEG: effects of a single dose, subchronic treatment, and discontinuation in healthy subjects. Neuropsychopharmacology 26: 246–258PubMedCrossRefGoogle Scholar
  22. 22.
    van Bemmel AL, van den Hoofdakker RH, Beersma DG, Bouhuys AL (1993) Changes in sleep polygraphic variables and clinical state in depressed patients during treatment with citalopram. Psychopharmacology (Berl) 113: 225–230CrossRefGoogle Scholar
  23. 23.
    Rush AJ, Armitage R, Gillin JC, Yonkers KA, Winokur A, Moldofsky H, Vogel GW, Kaplita SB, Fleming JB, Montplaisir J et al. (1998) Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. Biol Psychiatry 44: 3–14PubMedCrossRefGoogle Scholar
  24. 24.
    Wilson SJ, Bailey JE, Rich AS, Nash J, Adrover M, Tournoux A, Nutt DJ (2005) The use of sleep measures to compare a new 5HT1A agonist with buspirone in humans. J Psychopharmacol 19: 609–613PubMedCrossRefGoogle Scholar
  25. 25.
    Hicks JA, Argyropoulos SV, Rich AS, Nash JR, Bell CJ, Edwards C, Nutt DJ, Wilson SJ (2002) Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression. Br J Psychiatry 180: 528–535PubMedCrossRefGoogle Scholar
  26. 26.
    Lawlor BA, Newhouse PA, Balkin TJ, Molchan SE, Mellow AM, Murphy DL, Sunderland T (1991) A preliminary study of the effects of nighttime administration of the serotonin agonist, m-CPP, on sleep architecture and behavior in healthy volunteers. Biol Psychiatry 29: 281–286PubMedCrossRefGoogle Scholar
  27. 27.
    Oberndorfer S, Saletu-Zyhlarz G, Saletu B (2000) Effects of selective serotonin reuptake inhibitors on objective and subjective sleep quality. Neuropsychobiology 42: 69–81PubMedCrossRefGoogle Scholar
  28. 28.
    Borbely AA (1982) A two process model of sleep regulation. Hum Neurobiol 1: 195–204PubMedGoogle Scholar
  29. 29.
    Ehlers CL, Havstad JW, Kupfer DJ (1996) Estimation of the time course of slow-wave sleep over the night in depressed patients: effects of clomipramine and clinical response. Biol Psychiatry 39: 171–181PubMedCrossRefGoogle Scholar
  30. 30.
    Jindal RD, Friedman ES, Berman SR, Fasiczka AL, Howland RH, Thase TE (2003) Effects of sertraline on sleep architecture in patients with depression. J Clin Psychopharmacol 23: 540–548PubMedCrossRefGoogle Scholar
  31. 31.
    Veitch W, Wilson SJ, Argyropoulos S, Nash J, Hicks J, Nutt DJ (2001) Slow waves in sleep are altered by paroxetine and nefazodone in depressed patients. J Psychopharmacol (Oxf) 15: A18CrossRefGoogle Scholar
  32. 32.
    Chalon S, Pereira A, Lainey E, Vandenhende F, Watkin JG, Staner L, Granier LA (2005) Comparative effects of duloxetine and desipramine on sleep EEG in healthy subjects. Psychopharmacology (Berl) 177: 357–365CrossRefGoogle Scholar
  33. 33.
    Kluge M, Schussler P, Steiger A (2007) Duloxetine increases stage 3 sleep and suppresses rapid eye movement (REM) sleep in patients with major depression. Eur Neuropsychopharmacol 17: 527–531PubMedCrossRefGoogle Scholar
  34. 34.
    Lemoine P, Faivre T (2004) Subjective and polysomnographic effects of milnacipran on sleep in depressed patients. Hum Psychopharmacol 19: 299–303PubMedCrossRefGoogle Scholar
  35. 35.
    Olajide D, Lader M (1987) A comparison of buspirone, diazepam, and placebo in patients with chronic anxiety states. J Clin Psychopharmacol 7: 148–152PubMedCrossRefGoogle Scholar
  36. 36.
    Broocks A, Meyer T, Opitz M, Bartmann U, Hillmer-Vogel U, George A, Pekrun G, Wedekind D, Ruther E, Bandelow B (2003) 5-HT1A responsivity in patients with panic disorder before and after treatment with aerobic exercise, clomipramine or placebo. Eur Neuropsychopharmacol 13: 153–164PubMedCrossRefGoogle Scholar
  37. 37.
    Robinson DS, Sitsen JM, Gibertini M (2003) A review of the efficacy and tolerability of immediate-release and extended-release formulations of gepirone. Clin Ther 25: 1618–1633PubMedCrossRefGoogle Scholar
  38. 38.
    Evans SM, Troisi JR, Griffiths RR (1994) Tandospirone and alprazolam: comparison of behavioral effects and abuse liability in humans. J Pharmacol Exp Ther 271: 683–694PubMedGoogle Scholar
  39. 39.
    Fresquet A, Sust M, Lloret A, Murphy MF, Carter FJ, Campbell GM, Marion-Landais G (2000) Efficacy and safety of lesopitron in outpatients with generalized anxiety disorder. Ann Pharmacother 34: 147–153PubMedCrossRefGoogle Scholar
  40. 40.
    Rickels K, Derivan A, Kunz N, Pallay A, Schweizer E (1996) Zalospirone in major depression: a placebo-controlled multicenter study. J Clin Psychopharmacol 16: 212–217PubMedCrossRefGoogle Scholar
  41. 41.
    van Vliet IM, Westenberg HG, den Boer JA (1996) Effects of the 5-HT1A receptor agonist flesinoxan in panic disorder. Psychopharmacology (Berl) 127: 174–180CrossRefGoogle Scholar
  42. 42.
    Monti JM, Jantos H (2005) A study of the brain structures involved in the acute effects of fluoxetine on REM sleep in the rat. Int J Neuropsychopharmacol 8: 75–86PubMedCrossRefGoogle Scholar
  43. 43.
    Manfredi RL, Kales A, Vgontzas AN, Bixler EO, Isaac MA, Falcone CM (1991) Buspirone: sedative or stimulant effect? Am J Psychiatry 148: 1213–1217PubMedGoogle Scholar
  44. 44.
    Gillin JC, Sohn JW, Stahl SM, Lardon M, Kelsoe J, Rapaport M, Ruiz C, Golshan S (1996) Ipsapirone, a 5-HT1A agonist, suppresses REM sleep equally in unmedicated depressed patients and normal controls. Neuropsychopharmacology 15: 109–115PubMedCrossRefGoogle Scholar
  45. 45.
    Ansseau M, Pitchot W, Gonzalez-Moreno A, Papart P, Gerriston van der Hoop R, Bradford D (1992) Flesionxan, a 5HT1A agonist, in major depression: clinical efficacy and effects on REM latency and body temperature. Eur Neuropsychopharmacol 2: 313CrossRefGoogle Scholar
  46. 46.
    Ware JC, Rose FV, McBrayer RH (1994) The acute effects of nefazodone, trazodone and buspirone on sleep and sleep-related penile tumescence in normal subjects. Sleep 17: 544–550PubMedGoogle Scholar
  47. 47.
    Driver HS, Flanigan MJ, Bentley AJ, Luus HG, Shapiro CM, Mitchell D (1995) The influence of ipsapirone, a 5-HT1A agonist, on sleep patterns of healthy subjects. Psychopharmacology (Berl) 117: 186–192CrossRefGoogle Scholar
  48. 48.
    Seifritz E, Moore P, Trachsel L, Bhatti T, Stahl SM, Gillin JC (1996) The 5-HT1A agonist ipsapirone enhances EEG slow wave activity in human sleep and produces a power spectrum similar to 5-HT2 blockade. Neurosci Lett 209: 41–44PubMedCrossRefGoogle Scholar
  49. 49.
    Moore P, Seifritz E, Schlosser A, Greenfield D, Stahl S, Rapaport M, Kelsoe J (2001) Rapid tryptophan depletion plus a serotonin 1A agonist: competing effects on sleep in healthy men. Neuropsychopharmacology 25: S40–S44PubMedCrossRefGoogle Scholar
  50. 50.
    Sateia MJ, Doghramji K, Hauri PJ, Morin CM (2000) Evaluation of chronic insomnia. An American Academy of Sleep Medicine review. Sleep 23: 243–308PubMedGoogle Scholar
  51. 51.
    Parrott AC, Hindmarch I (1978) Factor analysis of a sleep evaluation questionnaire. Psychol Med 8: 325–329PubMedGoogle Scholar
  52. 52.
    Parrott AC, Hindmarch I (1980) The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigations — a review. Psychopharmacology (Berl) 71: 173–179CrossRefGoogle Scholar
  53. 53.
    Zisapel N, Laudon M (2003) Subjective assessment of the effects of CNS-active drugs on sleep by the Leeds sleep evaluation questionnaire: a review. Hum Psychopharmacol 18: 1–20PubMedCrossRefGoogle Scholar
  54. 54.
    Ware JC (1983) Tricyclic antidepressants in the treatment of insomnia. J Clin Psychiatry 44: 25–28PubMedGoogle Scholar
  55. 55.
    Mayers AG, van Hooff JC, Baldwin DS (2003) Quantifying subjective assessment of sleep and life-quality in antidepressant-treated depressed patients. Hum Psychopharmacol 18: 21–27PubMedCrossRefGoogle Scholar
  56. 56.
    Hutchinson DR, Tong S, Moon CA, Vince M, Clarke A (1992) Paroxetine in the treatment of elderly depressed patients in general practice: a double-blind comparison with amitriptyline. Int Clin Psychopharmacol 6Suppl 4: 43–51PubMedCrossRefGoogle Scholar
  57. 57.
    Staner L, Kerkhofs M, Detroux D, Leyman S, Linkowski P, Mendlewicz J (1995) Acute, subchronic and withdrawal sleep EEG changes during treatment with paroxetine and amitriptyline: a double-blind randomized trial in major depression. Sleep 18: 470–477PubMedGoogle Scholar
  58. 58.
    Dorman T (1992) Sleep and paroxetine: a comparison with mianserin in elderly depressed patients. Int Clin Psychopharmacol 6Suppl 4: 53–58PubMedGoogle Scholar
  59. 59.
    Satterlee WG, Faries D (1995) The effects of fluoxetine on symptoms of insomnia in depressed patients. Psychopharmacol Bull 31: 227–237PubMedGoogle Scholar
  60. 60.
    Dossenbach M, Martenyi FS, De Verga E (1997) Sleep quality during fluoxetine therapy in depression. Biol Psychiatry 42: 243SCrossRefGoogle Scholar
  61. 61.
    Stephenson DA, Harris B, Davies RH, Mullin JM, Richardson E, Boardman H, Meanley D, Banerjee A (2000) The impact of antidepressants on sleep and anxiety: a comparative study of fluoxetine and dothiepin using the Leeds Sleep Evaluation Questionnaire. Hum Psychopharmacol 15: 529–534PubMedCrossRefGoogle Scholar
  62. 62.
    Rosenberg C, Damsbo N, Fuglum E, Jacobsen LV, Horsgard S (1994) Citalopram and imipramine in the treatment of depressive patients in general practice. A Nordic multicentre clinical study. Int Clin Psychopharmacol 9Suppl 1: 41–48PubMedGoogle Scholar
  63. 63.
    Bech P, Cialdella P (1992) Citalopram in depression — meta-analysis of intended and unintended effects. Int Clin Psychopharmacol 6Suppl 5: 45–54PubMedCrossRefGoogle Scholar
  64. 64.
    Aguglia E, Casacchia M, Cassano GB, Faravelli C, Ferrari G, Giordano P, Pancheri P, Ravizza L, Trabucchi M, Bolino F (1993) Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. Int Clin Psychopharmacol 8: 197–202PubMedCrossRefGoogle Scholar
  65. 65.
    Bennie EH, Mullin JM, Martindale JJ (1995) A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. J Clin Psychiatry 56: 229–237PubMedGoogle Scholar
  66. 66.
    Sechter D, Troy S, Paternetti S, Boyer P (1999) A double-blind comparison of sertraline and fluoxetine in the treatment of major depressive episode in outpatients. Eur Psychiatry 14: 41–48PubMedCrossRefGoogle Scholar
  67. 67.
    Pagel JF, Helfter P (2003) Drug induced nightmares—an etiology based review. Hum Psychopharmacol 18: 59–67PubMedCrossRefGoogle Scholar
  68. 68.
    Markowitz JC (1991) Fluoxetine and dreaming. J Clin Psychiatry 52: 432PubMedGoogle Scholar
  69. 69.
    Lepkifker E, Dannon PN, Iancu I, Ziv R, Kotler M (1995) Nightmares related to fluoxetine treatment. Clin Neuropharmacol 18: 90–94PubMedCrossRefGoogle Scholar
  70. 70.
    Koponen H, Lepola U, Leinonen E, Jokinen R, Penttinen J, Turtonen J (1997) Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study. Acta Psychiatr Scand 96: 343–346PubMedCrossRefGoogle Scholar
  71. 71.
    Kirschner NT (1999) Medication and dreams: changes in dream content after drug treatment. Dreaming 9: 195–200CrossRefGoogle Scholar
  72. 72.
    Pace-Schott EF, Gersh T, Silvestri R, Stickgold R, Salzman C, Hobson JA (2001) SSRI treatment suppresses dream recall frequency but increases subjective dream intensity in normal subjects. J Sleep Res 10: 129–142PubMedCrossRefGoogle Scholar
  73. 73.
    Dilsaver SC, Greden JF (1984) Antidepressant withdrawal phenomena. Biol Psychiatry 19: 237–256PubMedCrossRefGoogle Scholar

Copyright information

© Birkhäuser Verlag/Switzerland 2008

Authors and Affiliations

  • Spilios V. Argyropoulos
    • 1
  • Sue J. Wilson
    • 2
  • David J. Nutt
    • 2
  1. 1.Section of Neurobiology of PsychosisInstitute of PsychiatryLondonUK
  2. 2.Psychopharmacology UnitBristolUK

Personalised recommendations